Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clemens-Martin Wendtner

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
Future Oncology (London, England)|February 22, 2018
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemiaPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
Frontiers in Immunology|April 9, 2021
SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 PatientsTatjana Schwarz, Kirsten Heiss, Yuvaraj Mahendran, et al.
International Journal of Molecular Sciences|October 26, 2024
Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept StudySatendra Kumar, Liangliang Nan, Georgia Kalodimou, et al.
Cancer Research|June 20, 2012
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemiaConstance Baer, Rainer Claus, Lukas P Frenzel, et al.
European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.
Haematologica|October 30, 2020
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Annals of Hematology|February 16, 2013
Acute leukemias of ambiguous lineage in adults: molecular and clinical characterizationSandra Heesch, Martin Neumann, Stefan Schwartz, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Future Oncology (London, England)|February 22, 2018
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemiaPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
Frontiers in Immunology|April 9, 2021
SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 PatientsTatjana Schwarz, Kirsten Heiss, Yuvaraj Mahendran, et al.
International Journal of Molecular Sciences|October 26, 2024
Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept StudySatendra Kumar, Liangliang Nan, Georgia Kalodimou, et al.
Cancer Research|June 20, 2012
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemiaConstance Baer, Rainer Claus, Lukas P Frenzel, et al.
European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.
Haematologica|October 30, 2020
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Annals of Hematology|February 16, 2013
Acute leukemias of ambiguous lineage in adults: molecular and clinical characterizationSandra Heesch, Martin Neumann, Stefan Schwartz, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
Pageof 11